PTGS2 and neoplasm: Clinical trials to develop an understanding of prostaglandin/COX-2 inhibition and immune checkpoint blockade therapeutic responses are underway in multiple tumor types [(151) NCT03396952, NCT03638297, NCT03864575, NCT03926338].